Latest

13:56
[ DAISHOMICROLINE(00567.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 21.27 million, loss widened by 0.69% YoY ] NewTimeSpace News: June 18, 2026, DAISHOMICROLINE(00567.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 43.43 million, decreased by 18.21% YoY
Tag： DAISHOMICROLINE00567.HKLoss widens
13:55
[ ELEPHANT HLDGS(08635.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 5.81 million, turned profitable from a loss YoY ] NewTimeSpace News: June 18, 2026, ELEPHANT HLDGS(08635.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 175 million, increased by 875.54% YoY
Tag： ELEPHANT HLDGS08635.HKturned profitable from a loss
13:54
[ CSOP STAR 50 Index ETF(03109.HK) Rises 0.54% Intraday, NAV Per Unit Stands at HK$18.551 ] NewTimeSpace News: As at 13:48 on June 22, 2026, CSOP STAR 50 Index ETF(03109.HK) edged up 0.54% to quote HK$18.620.
Tag： CSOP STAR 50 Index ETF03109.HKETF
13:54
[ CHINA HONGGUANG(08646.HK): Officially Expands New Material Business of TGV Glass-based Copper Clad Laminates ] NewTimeSpace News: China Hongguang Holdings Limited (08646.HK) announced that Guangdong Longguang New Material Technology Co., Limited, its indirectly wholly-owned subsidiary, has officially expanded the new material business of TGV glass-based copper clad laminates. Its products cover AI computing packaging substrates, automotive-grade energy storage electronic base materials and other fields. The industrial chain has been established in Shenzhen in the first half of 2026, and a trial production line will be launched in the second half of the year.
Tag： CHINA HONGGUANG08646.HKBusiness Development
13:54
[ ChinaAMC CSI Electricity Equipment Theme ETF(159326) rises 3.77%, aiming for a sixth consecutive gain ] NewTimeSpace (newtimespace.com) News, as of 13:48 on June 22, 2026, ChinaAMC Grid Equipment ETF (159326) rose 3.77%, aiming for a sixth consecutive gain. The latest price was 2.23 yuan.In terms of liquidity, ChinaAMC Grid Equipment ETF recorded an intraday turnover rate of 5.7% and a trading volume of 1.505 billion yuan. Over a longer time frame, as of June 18, the ETF's average daily trading volume over the past month reached 1.423 billion yuan.In terms of scale, the latest scale of ChinaAMC Grid Equipment ETF reached 25.734 billion yuan.
Tag： ETF159326.SZChinaAMC CSI Electricity Equipment Theme ETF
13:48
[ Ishares Nasdaq 100 Index Etf(02834.HK) Rises 0.69% Intraday at HK$582.000 ] NewTimeSpace News: As at 13:33 on June 22, 2026, Ishares Nasdaq 100 Index Etf(02834.HK) advanced 0.69% to trade at HK$582.00.
Tag： Ishares Nasdaq 100 Index Etf02834.HKETF
13:47
[ Penghua Guozheng Securities Champion Index ETF(159993) rises 6.14%, with the latest margin financing purchase amount reaching 4.9524 million yuan ] NewTimeSpace (newtimespace.com) News, as of 13:43 on June 22, 2026, Penghua Securities ETF (159993) rose 6.14%, with the latest price at 1.21 yuan.In terms of liquidity, Penghua Securities ETF recorded an intraday turnover rate of 6.83% and a trading volume of 251 million yuan. Over a longer time frame, as of June 18, the ETF's average daily trading volume over the past year reached 129 million yuan.In terms of scale, the latest scale of Penghua Securities ETF reached 3.532 billion yuan.
Tag： ETF159993.SZPenghua Guozheng Securities Champion Index ETF
13:45
[ FIRST PACIFIC(00142.HK): VITRO REIT, Subsidiary of Associate PLDT, Files IPO Registration Statement, Targeting Maximum Proceeds of PHP24.2 Billion ] NewTimeSpace News: First Pacific Co. Ltd. (00142.HK) announced that VITRO REIT under its principal operating associate PLDT Inc. has filed a registration statement and REIT scheme with the Securities and Exchange Commission of the Philippines, proposing an initial public offering on the Main Board of the Philippine Stock Exchange, which is expected to become the Philippines’ first digital infrastructure REIT. Assuming full exercise of the over-allotment option, the offer price is capped at PHP11.0 per share, with total gross proceeds projected to reach a maximum of PHP24.2 billion (approximately HK$3.1 billion).
Tag： FIRST PACIFIC00142.HKReal Estate Investment Trust
13:41
[ Southern FTSE China A50 ETF(02822.HK) Rises 0.73% Intraday at HK$16.470 ] NewTimeSpace News: As at 13:37 on June 22, 2026, Southern FTSE China A50 ETF (02822.HK) climbed 0.73% to quote HK$16.470.
Tag： Southern FTSE China A50 ETF02822.HKETF
13:40
[ ChinaAMC China Science And Technology Innovation Board Artificial Intelligence ETF (589010) falls 1.89%, with a scale increase of 114 million yuan over the past week ] NewTimeSpace (newtimespace.com) News, as of 13:34 on June 22, 2026, ChinaAMC STAR Artificial Intelligence ETF (589010) fell 1.89%, with the latest price at 1.65 yuan.In terms of scale, ChinaAMC STAR Artificial Intelligence ETF saw a significant increase of 114 million yuan in scale over the past week, with the new scale increase ranking 3/11 among comparable funds.In terms of shares, ChinaAMC STAR Artificial Intelligence ETF experienced a significant increase of 878 million units in share count over the past year, with the new share increase ranking 1/11 among comparable funds.
Tag： ETF589010.SHChinaAMC China Science And Technology Innovation Board Artificial Intelligence ETF
13:37
[ SSY GROUP(02005.HK): NMPA Grants Manufacturing Approval for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution ] NewTimeSpace News: SSY Group Limited (02005.HK) announced that the Group has obtained manufacturing registration approvals from the National Medical Products Administration (NMPA) for two pharmaceutical products. Safinamide Mesylate Tablets (100mg & 50mg), classified as Class 4 chemical drugs and deemed to have passed consistency evaluation, make SSY the third domestic pharmaceutical firm to secure approval for this product. Meanwhile, Procaterol Hydrochloride Inhalation Solution (0.3ml:30μg), a Class 3 chemical drug, also received registration approval with deemed consistency evaluation clearance.
Tag： SSY Group02005.HKmanufacturing registration approval certificate
13:37
[ ChinaAMC NASDAQ 100 ETF(03086.HK) Rises 0.81% Intraday, Average Traded Price at HK$61.781 ] NewTimeSpace News: As at 13:30 on June 22, 2026, ChinaAMC NASDAQ 100 ETF(03086.HK) gained 0.81% to quote HK$61.880.
Tag： ChinaAMC NASDAQ 100 ETF03086.HKETF
13:32
[ AI Chip Concept Stocks Watch | ASMPT (00522.HK) Fluctuates and Decreases; Institutions Point Out Domestic AI Chips Are Welcoming a Price Hike Window ] NewTimeSpace (newtimespace.com) News: On June 22, 2026, the chip sector experienced a volatile trading trend. ASMPT (00522.HK) opened lower and fluctuated, with the company's share price quoted at HK$202.400, down 3.07% as of 13:25 PM.
Tag： NewTimeSpaceASMPT00522.HK
13:31
[ iShares CSI 300 A-Share Index ETF(02846.HK) Rises 1.09% Intraday, AUM Reaches HK$8.462 Billion ] NewTimeSpace News: As at 13:26 on June 22, 2026, iShares CSI 300 A-Share Index ETF(02846.HK) advanced 1.09% to trade at HK$39.120.
Tag： iShares CSI 300 A-Share Index ETF02846.HKETF
13:29
[ SIHUAN PHARM(00460.HK): First Patient Dosed in Phase III Trial of Anaprazole Sodium from Xuanzhu Biologics for Helicobacter Pylori Eradication ] NewTimeSpace News: Sihuan Pharmaceutical Holdings Group Ltd. (00460.HK) announced that the Phase III clinical study of self-developed innovative drug Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®) from its non-wholly-owned subsidiary Xuanzhu Biologics, evaluating bismuth quadruple therapy containing Anaprazole Sodium for Helicobacter pylori eradication, has completed the first patient dosing, marking the official launch of this pivotal registrational clinical trial.
Tag： SIHUAN PHARM00460.HKClinical Trial
13:25
[ Db X-Trackers FTSE Vietnam UCITS ETF(03087.HK) Rises 0.90% Intraday at HK$326.80 ] NewTimeSpace News: As at 13:14 on June 22, 2026, Db X-Trackers FTSE Vietnam UCITS ETF(03087.HK) climbed 0.90% to quote HK$326.800.
Tag： Db X-Trackers FTSE Vietnam UCITS ETF03087.HKETF
13:25
[ INNOGEN-B(02591.HK): Ib-stage Clinical Trial of Efsubaglutide Alfa for Adolescent Obesity Approved, Expected to Kick Off in July ] NewTimeSpace News: Guangzhou Innogen Pharmaceutical Group Co., Ltd. (02591.HK) announced that the Group obtained approval from the NMPA on 17 June 2026 to launch an Ib-stage clinical trial of Efsubaglutide Alfa for the treatment of adolescent obesity. The trial is scheduled to commence in July 2026, with a planned enrollment of approximately 36 participants.
Tag： INNOGEN-B02591.HKClinical Trial
13:20
[ HANXBIO-B(03378.HK) Included in FTSE Global Micro Cap Index ] NewTimeSpace News: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (03378.HK) announced that pursuant to FTSE Russell’s quarterly index review, the Company has been admitted to the FTSE Global Micro Cap Index under the FTSE Global Equity Index Series, with the inclusion effective after market close on 19 June 2026. The Board believes this inclusion broadly recognises the Company’s solid fundamentals, innovation capacity and growth potential from international capital markets, expected to lift its visibility among global institutional investors and analysts, attract inflows from passive and active funds tracking relevant indices, diversify shareholder base and enhance trading liquidity of its shares.
Tag： HANXBIO-B03378.HKFTSE Russell
13:17
[ Humanoid Robot Concept Stocks Watch | Robot Concept Sector Fluctuates and Weakens; Xiaomi Corporation-W (01810.HK) Drops Nearly 4% Intraday ] NewTimeSpace (newtimespace.com) News: On June 22, 2026, the robot concept sector fluctuated and weakened. Xiaomi Corporation-W (01810.HK) continued to open lower and move downward. As of 13:05 PM, the company's share price was quoted at HK$23.600, down 3.99%.
Tag： NewTimeSpaceXIAOMI-W01810.HK
13:16
[ INSILICO(03696.HK) Enters AI-Powered R&D Collaboration with SK Biopharmaceuticals, Total Potential Deal Value Exceeds USD2.5 Billion ] NewTimeSpace News: InSilico(03696.HK) announced a research and development collaboration with SK Biopharmaceuticals to discover AI-driven novel drug candidates targeting neuroimmune disorders of the central nervous system. Under the agreement, InSilico Medicine is eligible for upfront and near-term milestone payments of up to USD18 million, with the total potential deal value surpassing USD2.5 billion, covering development, regulatory and commercial milestones plus single-digit tiered royalties on net sales post-launch.
Tag： Insilico03696.HKResearch and Development Collaboration
Previous1..367368 369370371..577     577 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments